RDY
Dr. Reddy`s Laboratories Ltd.
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
They are an Indian multinational pharmaceutical company located in Hyderabad, Telangana, India. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited.
Market Cap: 12.6 Billion
Primary Exchange: NEW YORK STOCK EXCHANGE INC.
Website: http://www.drreddys.com/
Shares Outstanding: 167 Million
Float: 0
Dividend: 0.4826079905033112 (0.01%)
Beta: 0.1735060285999698
Sector: Manufacturing
Industry: Medicinal and Botanical Manufacturing
Ethical Flags
Longest drawdown: 1394 trading days
From: 2015-10-19 To: 2020-09-17
Lowest Point:
Teva hits 19-year low on continued pricing pressure
via: SeekingAlpha at 2019-06-12 06:49:59:000
Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...
Teva hits 19-year low on continued pricing pressure
via: SeekingAlpha at 2019-06-12 06:49:59:000
Teva Pharmaceutical Industries ( TEVA -4.2% ) slumps on modestly higher volume. Shares are now exchanging hands at the lowest prices in 19 years. The stock continues to fight pricing headwinds, the continued erosion of Copaxone sales (down 56% in Q1) and its potential exposure from opioid … read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
FDA Ad Com tomorrow on utility of higher-dose opioids
via: SeekingAlpha at 2019-06-10 13:06:51:000
The FDA's Anesthetic and Analgesic Drug Products Advisory Committee and the Drug Safety and Risk Management Advisory Committee will jointly mee t tomorrow and Wednesday, June 11 & 12, to seek public input on the clinical utility and safety concerns associated with higher range opioid an… read more...
Dr. Reddy's Lab reports positive mid-stage data in plaque psoriasis study
via: SeekingAlpha at 2019-06-10 02:35:16:000
Dr. Reddys Laboratories (NYSE: RDY ) has announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis. More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Read m… read more...
Dr. Reddy's Lab reports positive mid-stage data in plaque psoriasis study
via: SeekingAlpha at 2019-06-10 02:35:16:000
Dr. Reddys Laboratories (NYSE: RDY ) has announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate to severe plaque psoriasis. More news on: Dr. Reddy's Laboratories Limited, Healthcare stocks news, Read m… read more...
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy's Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis
via: Business Wire at 2019-06-09 22:42:00:000
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate… read more...
Dr. Reddy's Laboratories Limited Through Its Wholly Owned Subsidiary, Dr. Reddy's Laboratories SA, Announces Positive Topline Results from Phase 2b Study of PPC-06 in Patients with Moderate to Severe Plaque Psoriasis
via: Business Wire at 2019-06-09 22:42:00:000
Dr. Reddys Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as Dr. Reddys) announced positive topline results from its Phase 2b study of PPC-06 (formerly referred to as XP23829) in patients with moderate… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|---|---|---|---|---|---|---|---|
| 2020-07-10 | 2020-07-13 | 2020-06-26 | 0.330398 | Cash | ||||
| 2022-08-01 | 2022-08-12 | 2022-07-11 | 2022-05-24 | 0.378434 | Cash | |||
| 2023-07-07 | 2023-07-10 | 2023-05-11 | 0.487669 | Cash | ||||
| 2023-07-28 | 2023-07-10 | 2023-05-11 | 0.487669 | Cash |
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|